Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Program Description

Myeloproliferative neoplasms (MPNs) are rare, chronic blood cancers arising from hematopoietic stem cells, characterized by overproduction of myeloid cells. MPNs are often underdiagnosed due to nonspecific symptoms, making molecular testing central to diagnosis and treatment planning. Novel agents and combination strategies are continually being investigated to address unmet needs, particularly for patients with suboptimal responses or resistance to JAK inhibitors. Oncology pharmacists play a critical role in precision medicine for MPNs, and their interventions require familiarity with molecular mutation data, the ability to discern treatment plans, and multidisiciplinary communication within the care team. They are integral to the design and implementation of patient-specific management plans for treatment-related toxicities, ensuring evidence-based supportive care is planned and implemented promptly. This session will focus on MPN symptom assessment, treatment algorithms, and emerging targeted therapies for MPNs to inform the oncology pharmacist's role in precision medicine using molecular data to guide treatment. This interactive session features patient case examples that will review shared decision-making and considerations for treatment of patients with MPNs.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: December 5, 2025
Expiration date: December 5, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explain the clinical implications of common myeloproliferative neoplasm driver mutations and mechanisms of JAK/ BET/LSD1 inhibitors, combination regimens, and emerging targeted/precision therapies
2. Use validated symptom scoring tools to recommend pharmacologic and nonpharmacologic treatments for common symptoms
3. Employ strategies to help patients navigate challenges surrounding insurance approvals, financial support, and trial referrals

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-401-H01-P. The activity is available for CE credit through December 5, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Victoria Nachar, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Beigene, GSK

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms